Abstract
Animal behavioural profiles are commonly employed to investigate new therapeutic agents to treat anxiety disorders as well as to investigate the mechanism of action of anxiolytic drugs. However, many clinically important symptoms of anxiety can not be modelled directly in animals. Human models of anxiety should bridge between animal models and anxiety disorders. Experimental anxiety states in humans can be induced by either pharmacological means such as CO2 inhalation or psychological means such as aversive conditioning of skin conductance responses to tones. Investigation of these models may contribute to a better understanding of anxiety disorders, both from a biological and behavioural point of view. In a comprehensive review existing models of human experimental anxiety states are summarized and validity is discussed.
Keywords: Anxiety, model, anxiolytic, drug development, humans
Current Neuropharmacology
Title: Modelling Anxiety in Humans for Drug Development
Volume: 5 Issue: 1
Author(s): Martin Siepmann and Peter Joraschky
Affiliation:
Keywords: Anxiety, model, anxiolytic, drug development, humans
Abstract: Animal behavioural profiles are commonly employed to investigate new therapeutic agents to treat anxiety disorders as well as to investigate the mechanism of action of anxiolytic drugs. However, many clinically important symptoms of anxiety can not be modelled directly in animals. Human models of anxiety should bridge between animal models and anxiety disorders. Experimental anxiety states in humans can be induced by either pharmacological means such as CO2 inhalation or psychological means such as aversive conditioning of skin conductance responses to tones. Investigation of these models may contribute to a better understanding of anxiety disorders, both from a biological and behavioural point of view. In a comprehensive review existing models of human experimental anxiety states are summarized and validity is discussed.
Export Options
About this article
Cite this article as:
Siepmann Martin and Joraschky Peter, Modelling Anxiety in Humans for Drug Development, Current Neuropharmacology 2007; 5 (1) . https://dx.doi.org/10.2174/157015907780077114
DOI https://dx.doi.org/10.2174/157015907780077114 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurophysiological Alterations in the Prepsychotic Phases
Current Pharmaceutical Design Antifungal Therapy of Aspergillosis of the Central Nervous System and Aspergillus Endophthalmitis
Current Pharmaceutical Design Ketamine as Antidepressant? Current State and Future Perspectives
Current Neuropharmacology Neurotoxicity of Insecticides
Current Medicinal Chemistry Amplicon Vectors as Outstanding Tools to Study and Modify Cognitive Functions
Current Gene Therapy Targeting the NMDA Receptor for Fear-Related Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Physiologic Responses in Anxiety
Current Psychiatry Reviews Nicotinic Receptors Containing the α7 Subunit: A Model for Rational Drug Design
Current Medicinal Chemistry Brain Magnetic Stimulation in Animal Models: A Valuable Lesson for Clinical Applications
CNS & Neurological Disorders - Drug Targets Definition of Genes and Paths Involved in Alzheimers Disease: Using Gene Expression Profiles and Chemical Genetics at the Mouse Brain Level
Current Genomics Auditory and Visual Mismatch Negativity in Psychiatric Disorders: A Review
Current Psychiatry Reviews Functional Activity and Connectivity Differences of Five Resting-State Networks in Patients with Alzheimer’s Disease or Mild Cognitive Impairment
Current Alzheimer Research The Synthetic Cannabinoids Phenomenon
Current Pharmaceutical Design Kv7 Channels as Targets for the Treatment of Pain
Current Pharmaceutical Design Mind-Body Practices and the Adolescent Brain: Clinical Neuroimaging Studies
Adolescent Psychiatry Editorial (Thematic Issue: Neurobiological and Neurocognitive Basis of the Effects of Cannabinoids in Animals and Man: Therapeutic Potential of Cannabinoids in Psychiatry)
Current Pharmaceutical Design Bipolar Affective Disorder, Epilepsy and Migraine – Does Possible Shared Pathogenesis Explain their Association?
Current Psychopharmacology Startle Response Modulation as a Behavioral Tool in Neuropharmacology
Current Neuropharmacology Novel Therapies for Schizophrenia: Understanding the Glutamatergic Synapse and Potential Targets for Altering N-methyl-D-aspartate Neurotransmission
Recent Patents on CNS Drug Discovery (Discontinued) Targeting of Peripherally Expressed Pain-Related Molecules in Injury- Induced Chronic Neuropathic Pain
CNS & Neurological Disorders - Drug Targets